FDA gives nod to BrainStorm for ALS trial after Phase III flop
BrainStorm Cell Therapeutics will be initiating a Phase IIIb confirmatory trial of its lead candidate NurOwn after discussions with the…
BrainStorm Cell Therapeutics will be initiating a Phase IIIb confirmatory trial of its lead candidate NurOwn after discussions with the…
In May 2023, pharma giant Eli Lilly looked as if it was onto a winner after publishing positive topline data…
Amylyx Pharmaceuticals’s Phase III trial for amyotrophic lateral sclerosis (ALS) Relyvrio has failed to meet any of its endpoints. Following…
AC Immune is looking ahead to the second part of its Phase II Parkinson’s disease (PD) vaccine trial. The Swiss…
Changing the language used in trial protocols and continually conversing with sites are some ways by which trialists can make…
The US Food and Drug Administration (FDA) is focusing on how artificial intelligence (AI) can be used to support clinical…
Pharma and biotechs have shared concerns about working with large CROs, saying that the ‘one-stop shop’ model is no longer…
Lord James O’Shaughnessy, who created an in-depth report on the UK’s commercial clinical trial landscape after a significant decrease in…
After a busy two-day discussion about what needs to be done to improve the UK’s contribution to clinical trials, there…
Cancer Research UK (CRUK) is soon to move away from its UK-centric model as it is in conversation with other…